New-Onset Diabetes After Renal Transplantation: Diagnosis, Incidence, Risk Factors, Impact on Outcomes, and Novel Implications

Abstract Objective New-onset diabetes after transplantation (NODAT) is a multifactorial, complex metabolic disorder associated with impaired long-term graft function, reduced recipient survival, and increased risks of cardiovascular disease and infectious complications. The impact of NODAT is genera...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Transplantation proceedings 2011-06, Vol.43 (5), p.1375-1394
Hauptverfasser: Kaposztas, Z, Gyurus, E, Kahan, B.D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1394
container_issue 5
container_start_page 1375
container_title Transplantation proceedings
container_volume 43
creator Kaposztas, Z
Gyurus, E
Kahan, B.D
description Abstract Objective New-onset diabetes after transplantation (NODAT) is a multifactorial, complex metabolic disorder associated with impaired long-term graft function, reduced recipient survival, and increased risks of cardiovascular disease and infectious complications. The impact of NODAT is generally underestimated partly due to the inconsistent criteria that have been previously used for its diagnosis and to the generally short observation periods. The aim of this article was to review the recent literature on NODAT and to highlight the novel implications. Findings The 2010 American Diabetes Association guidelines provide useful, simplified criteria to unify the diagnosis including application of hemoglobin A1C levels. We sought to establish the impact of various modifiable and nonmodifiable risk factors. A vast number of papers have examined the effects of immunosuppressive medications on the development of NODAT: Neither calcineurin inhibitor nor sirolimus (SRL) or steroids seems to be innocent of contributing to it. Immunosuppressants account for 74% of the occurrence of NODAT. Among modifiable risk factors, obesity is independent and significant, with great prevalence in the population. In additional to lifestyle modifications, the role of bariatric surgery (BS) either before or after transplantation is highlighted herein as a strategy to reduce disease in the view of the results among overweight, nontransplanted patients. Summary Because of the strong association between high glucose values in the early posttransplant period and the development of NODAT, the condition must be recognized early after (or even before) transplantation by intensive screening. Patients at risk for NODAT must modify appropriate risk factors and particularly undergo pretransplant planning and/or posttransplant adjustment individualizing immunosuppressive therapy to mitigate the risk of this serious complication.
doi_str_mv 10.1016/j.transproceed.2011.04.008
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_873493924</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041134511006944</els_id><sourcerecordid>873493924</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-b6fd024d5147c1af0549561d020d89a8e7da92bf9ef8cb151dfcbb78804bd923</originalsourceid><addsrcrecordid>eNqNkk1v1DAQhi0EotuFv4AsJMSlCXbifPWAVLUUKlVdqezdcuwJ8jZrLx6nqBd-e53uViBOnGzPvPOO_XgIec9ZzhmvP23yGJTDXfAawOQF4zxnImesfUEWvG3KrKiL8iVZMCZ4xktRHZFjxA1L50KUr8lRweuuLJhYkN838CtbOYRIL6zqIQLSsyFCoLfg1EjXT51G5aKK1rvTWfXDebR4Qq-ctgachhN6a_GOXiodfZgT213aUu_oaorabyHFlDP0xt_DOGdHq5_s8A15NagR4e1hXZL15Zf1-bfsevX16vzsOtOiFjHr68GwQpiKi0ZzNbBKdFXNU4yZtlMtNEZ1RT90MLS65xU3g-77pm2Z6E1XlEvycW-bmP2cAKPcWtQwpneBn1AmZqIruwRnSU73Sh08YoBB7oLdqvAgOZMzfbmRf9OXM33JhEz0U_G7Q5up36bcc-kz7iT4cBAo1GockpG2-EcnBGtEN-su9jpITO4tBInazqSNDaCjNN7-330-_2OjR-sS-_EOHgA3fgrpj1FyiYVk8vs8L_O4cM5Y3QlRPgLUzb_W</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>873493924</pqid></control><display><type>article</type><title>New-Onset Diabetes After Renal Transplantation: Diagnosis, Incidence, Risk Factors, Impact on Outcomes, and Novel Implications</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Kaposztas, Z ; Gyurus, E ; Kahan, B.D</creator><creatorcontrib>Kaposztas, Z ; Gyurus, E ; Kahan, B.D</creatorcontrib><description>Abstract Objective New-onset diabetes after transplantation (NODAT) is a multifactorial, complex metabolic disorder associated with impaired long-term graft function, reduced recipient survival, and increased risks of cardiovascular disease and infectious complications. The impact of NODAT is generally underestimated partly due to the inconsistent criteria that have been previously used for its diagnosis and to the generally short observation periods. The aim of this article was to review the recent literature on NODAT and to highlight the novel implications. Findings The 2010 American Diabetes Association guidelines provide useful, simplified criteria to unify the diagnosis including application of hemoglobin A1C levels. We sought to establish the impact of various modifiable and nonmodifiable risk factors. A vast number of papers have examined the effects of immunosuppressive medications on the development of NODAT: Neither calcineurin inhibitor nor sirolimus (SRL) or steroids seems to be innocent of contributing to it. Immunosuppressants account for 74% of the occurrence of NODAT. Among modifiable risk factors, obesity is independent and significant, with great prevalence in the population. In additional to lifestyle modifications, the role of bariatric surgery (BS) either before or after transplantation is highlighted herein as a strategy to reduce disease in the view of the results among overweight, nontransplanted patients. Summary Because of the strong association between high glucose values in the early posttransplant period and the development of NODAT, the condition must be recognized early after (or even before) transplantation by intensive screening. Patients at risk for NODAT must modify appropriate risk factors and particularly undergo pretransplant planning and/or posttransplant adjustment individualizing immunosuppressive therapy to mitigate the risk of this serious complication.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2011.04.008</identifier><identifier>PMID: 21693204</identifier><identifier>CODEN: TRPPA8</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Biological and medical sciences ; Diabetes Mellitus - epidemiology ; Diabetes Mellitus - etiology ; Diabetes. Impaired glucose tolerance ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; Immunosuppressive Agents - administration &amp; dosage ; Incidence ; Kidney Transplantation - adverse effects ; Medical sciences ; Risk Factors ; Surgery ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the urinary system ; Tissue, organ and graft immunology ; Treatment Outcome</subject><ispartof>Transplantation proceedings, 2011-06, Vol.43 (5), p.1375-1394</ispartof><rights>Elsevier Inc.</rights><rights>2011 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c464t-b6fd024d5147c1af0549561d020d89a8e7da92bf9ef8cb151dfcbb78804bd923</citedby><cites>FETCH-LOGICAL-c464t-b6fd024d5147c1af0549561d020d89a8e7da92bf9ef8cb151dfcbb78804bd923</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.transproceed.2011.04.008$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,46002</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24407494$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21693204$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaposztas, Z</creatorcontrib><creatorcontrib>Gyurus, E</creatorcontrib><creatorcontrib>Kahan, B.D</creatorcontrib><title>New-Onset Diabetes After Renal Transplantation: Diagnosis, Incidence, Risk Factors, Impact on Outcomes, and Novel Implications</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>Abstract Objective New-onset diabetes after transplantation (NODAT) is a multifactorial, complex metabolic disorder associated with impaired long-term graft function, reduced recipient survival, and increased risks of cardiovascular disease and infectious complications. The impact of NODAT is generally underestimated partly due to the inconsistent criteria that have been previously used for its diagnosis and to the generally short observation periods. The aim of this article was to review the recent literature on NODAT and to highlight the novel implications. Findings The 2010 American Diabetes Association guidelines provide useful, simplified criteria to unify the diagnosis including application of hemoglobin A1C levels. We sought to establish the impact of various modifiable and nonmodifiable risk factors. A vast number of papers have examined the effects of immunosuppressive medications on the development of NODAT: Neither calcineurin inhibitor nor sirolimus (SRL) or steroids seems to be innocent of contributing to it. Immunosuppressants account for 74% of the occurrence of NODAT. Among modifiable risk factors, obesity is independent and significant, with great prevalence in the population. In additional to lifestyle modifications, the role of bariatric surgery (BS) either before or after transplantation is highlighted herein as a strategy to reduce disease in the view of the results among overweight, nontransplanted patients. Summary Because of the strong association between high glucose values in the early posttransplant period and the development of NODAT, the condition must be recognized early after (or even before) transplantation by intensive screening. Patients at risk for NODAT must modify appropriate risk factors and particularly undergo pretransplant planning and/or posttransplant adjustment individualizing immunosuppressive therapy to mitigate the risk of this serious complication.</description><subject>Biological and medical sciences</subject><subject>Diabetes Mellitus - epidemiology</subject><subject>Diabetes Mellitus - etiology</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration &amp; dosage</subject><subject>Incidence</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Medical sciences</subject><subject>Risk Factors</subject><subject>Surgery</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the urinary system</subject><subject>Tissue, organ and graft immunology</subject><subject>Treatment Outcome</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkk1v1DAQhi0EotuFv4AsJMSlCXbifPWAVLUUKlVdqezdcuwJ8jZrLx6nqBd-e53uViBOnGzPvPOO_XgIec9ZzhmvP23yGJTDXfAawOQF4zxnImesfUEWvG3KrKiL8iVZMCZ4xktRHZFjxA1L50KUr8lRweuuLJhYkN838CtbOYRIL6zqIQLSsyFCoLfg1EjXT51G5aKK1rvTWfXDebR4Qq-ctgachhN6a_GOXiodfZgT213aUu_oaorabyHFlDP0xt_DOGdHq5_s8A15NagR4e1hXZL15Zf1-bfsevX16vzsOtOiFjHr68GwQpiKi0ZzNbBKdFXNU4yZtlMtNEZ1RT90MLS65xU3g-77pm2Z6E1XlEvycW-bmP2cAKPcWtQwpneBn1AmZqIruwRnSU73Sh08YoBB7oLdqvAgOZMzfbmRf9OXM33JhEz0U_G7Q5up36bcc-kz7iT4cBAo1GockpG2-EcnBGtEN-su9jpITO4tBInazqSNDaCjNN7-330-_2OjR-sS-_EOHgA3fgrpj1FyiYVk8vs8L_O4cM5Y3QlRPgLUzb_W</recordid><startdate>20110601</startdate><enddate>20110601</enddate><creator>Kaposztas, Z</creator><creator>Gyurus, E</creator><creator>Kahan, B.D</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110601</creationdate><title>New-Onset Diabetes After Renal Transplantation: Diagnosis, Incidence, Risk Factors, Impact on Outcomes, and Novel Implications</title><author>Kaposztas, Z ; Gyurus, E ; Kahan, B.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-b6fd024d5147c1af0549561d020d89a8e7da92bf9ef8cb151dfcbb78804bd923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Biological and medical sciences</topic><topic>Diabetes Mellitus - epidemiology</topic><topic>Diabetes Mellitus - etiology</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration &amp; dosage</topic><topic>Incidence</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Medical sciences</topic><topic>Risk Factors</topic><topic>Surgery</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the urinary system</topic><topic>Tissue, organ and graft immunology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaposztas, Z</creatorcontrib><creatorcontrib>Gyurus, E</creatorcontrib><creatorcontrib>Kahan, B.D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaposztas, Z</au><au>Gyurus, E</au><au>Kahan, B.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New-Onset Diabetes After Renal Transplantation: Diagnosis, Incidence, Risk Factors, Impact on Outcomes, and Novel Implications</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2011-06-01</date><risdate>2011</risdate><volume>43</volume><issue>5</issue><spage>1375</spage><epage>1394</epage><pages>1375-1394</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><coden>TRPPA8</coden><abstract>Abstract Objective New-onset diabetes after transplantation (NODAT) is a multifactorial, complex metabolic disorder associated with impaired long-term graft function, reduced recipient survival, and increased risks of cardiovascular disease and infectious complications. The impact of NODAT is generally underestimated partly due to the inconsistent criteria that have been previously used for its diagnosis and to the generally short observation periods. The aim of this article was to review the recent literature on NODAT and to highlight the novel implications. Findings The 2010 American Diabetes Association guidelines provide useful, simplified criteria to unify the diagnosis including application of hemoglobin A1C levels. We sought to establish the impact of various modifiable and nonmodifiable risk factors. A vast number of papers have examined the effects of immunosuppressive medications on the development of NODAT: Neither calcineurin inhibitor nor sirolimus (SRL) or steroids seems to be innocent of contributing to it. Immunosuppressants account for 74% of the occurrence of NODAT. Among modifiable risk factors, obesity is independent and significant, with great prevalence in the population. In additional to lifestyle modifications, the role of bariatric surgery (BS) either before or after transplantation is highlighted herein as a strategy to reduce disease in the view of the results among overweight, nontransplanted patients. Summary Because of the strong association between high glucose values in the early posttransplant period and the development of NODAT, the condition must be recognized early after (or even before) transplantation by intensive screening. Patients at risk for NODAT must modify appropriate risk factors and particularly undergo pretransplant planning and/or posttransplant adjustment individualizing immunosuppressive therapy to mitigate the risk of this serious complication.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>21693204</pmid><doi>10.1016/j.transproceed.2011.04.008</doi><tpages>20</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0041-1345
ispartof Transplantation proceedings, 2011-06, Vol.43 (5), p.1375-1394
issn 0041-1345
1873-2623
language eng
recordid cdi_proquest_miscellaneous_873493924
source MEDLINE; Access via ScienceDirect (Elsevier)
subjects Biological and medical sciences
Diabetes Mellitus - epidemiology
Diabetes Mellitus - etiology
Diabetes. Impaired glucose tolerance
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Fundamental and applied biological sciences. Psychology
Fundamental immunology
Humans
Immunosuppressive Agents - administration & dosage
Incidence
Kidney Transplantation - adverse effects
Medical sciences
Risk Factors
Surgery
Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases
Surgery of the urinary system
Tissue, organ and graft immunology
Treatment Outcome
title New-Onset Diabetes After Renal Transplantation: Diagnosis, Incidence, Risk Factors, Impact on Outcomes, and Novel Implications
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T05%3A22%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New-Onset%20Diabetes%20After%20Renal%20Transplantation:%20Diagnosis,%20Incidence,%20Risk%20Factors,%20Impact%20on%20Outcomes,%20and%20Novel%20Implications&rft.jtitle=Transplantation%20proceedings&rft.au=Kaposztas,%20Z&rft.date=2011-06-01&rft.volume=43&rft.issue=5&rft.spage=1375&rft.epage=1394&rft.pages=1375-1394&rft.issn=0041-1345&rft.eissn=1873-2623&rft.coden=TRPPA8&rft_id=info:doi/10.1016/j.transproceed.2011.04.008&rft_dat=%3Cproquest_cross%3E873493924%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=873493924&rft_id=info:pmid/21693204&rft_els_id=S0041134511006944&rfr_iscdi=true